Abstract:BACKGROUND:To investigate on the expressions and the clinical significances of hepatocyte growth factor receptor (c-MET), phosphorylated c-MET (p-MET) and e2f-1 transcription factor in primary lesion of gastric adenocarcinoma (GC).METHOD:Tissue samples from the primary lesion of GC in patients who accepted D2/D3 radical gastrectomy with R0/R1 resection were stained by immunohistochemistry of c-MET, p-MET, e2f-1 and Ki-67. The univariate and the multivariate analyses involving in clinicopathological parameters and prognostic factors were evaluated.RESULTS:The positivity rates for c-MET (66.12%, 80 cases/121 cases), p-MET (59.50%, 72 cases/121 cases), e2f-1 (38.84%, 47 cases/121 cases) and Ki-67 (72.73%, 88 cases/121 cases) in primary lesion of GC was significantly higher than that in non-cancerous tissue at 5 cm places far from the margin of primary lesion (P < 0.05, respectively). The deeper tumor invasion, the severer lymph node metastasis, the later stage of TNM and the higher expression of Ki-67 was respectively an independent risk factor for the higher expression of c-MET or p-MET, but the younger age and the shorter survival time was an independent risk factor for the higher expression of e2f-1 respectively. Survival analysis showed that the worse prognosis could be observed in the patients with the combination of both c-MET-positive and e2f-1-negative (P = 0.038) or both p-MET-positive and e2f-1-negative (P = 0.042). Cox analysis demonstrated that the severer lymphatic node metastasis and the higher positivity rate of c-MET, p-MET or e2f-1 were an independent prognosis factor respectively. The higher expression of e2f-1 was identified in patients with Stage I-II, which correlated with a shorter survival time. Survival analysis also revealed that the prognosis of patients with positive expression of e2f-1 at Stage I-II was significantly worse than that in patients with negative expression of e2f-1 (χ2 = 13.437, P = 0.001). However, in the cases with Stage III-IV, no significant difference could be identified in the prognostic comparison between positive and negative expressions of e2f-1.CONCLUSIONS:The expression of c-MET or p-MET is an independent prognosis factor. It has been observed that the higher expression of e2f-1 occurred in the early stages while the lower expression of it in the later stages in GC.

Clinicopathological Significance of Expressions of C-Myc and E2F1 Proteins in Neuroendocrine Lung Carcinoma

Expression and clinical significance of ezrin in non--small-cell lung cancer.

Expressions and Clinical Significances of C-Met, P-Met and E2f-1 in Human Gastric Carcinoma

Expression of P21, P53 and C-Erbb-2 in Tissues of Non-Small Cell Lung Cancer and Its Clinical Significance

Expression of phospho-MAPK in non-small cell cancer and its clinicopathological significance

[Study on the Specific Expressions of P53, Bcl-2 and C-Myc in Non-Small Cell Lung Cancer with Neuroendocrine Differentiation].

Clinicopathological Significance of Expression of Fragile Histidine Triad Protein in Neuroendocrine Lung Carcinoma

Prognostic Significance of Overexpressed Matrix Metalloproteinase-2, Mouse-Double Minute: 2 Homolog and Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

Clinicopathological and Prognostic Significance of ERα and ERβ Expression in Lung Carcinomas: a Tissue Microarray Study

Clinical Significance of Expression C-Ets-1 Endometrial Carcinoma Tissue

Expression of P53,mrp and C-Erbb2 in Non-Small Cell Lung Cancer and Its Clinicopathological Significance

C-Met As a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome

Expressions of cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer

Prognostic Value of High FoxC2 Expression in Resectable Non-Small Cell Lung Cancer, Alone or in Combination with E-cadherin Expression.

Clinicopathological Significance of E-Cadherin and PCNA Expression in Human Non-Small Cell Lung Cancer

Prognostic Role of E2F1 Gene Expression in Human Cancer: a Meta-Analysis

Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer

Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Clear Cell Renal Cell Carcinoma

Positive Expression of P53, C-Erbb2 and MRP Proteins is Correlated with Survival Rates of NSCLC Patients.

The relationship between the expression and clinical significance of Nrf2 and Bcl-2 in esophageal squamous cell carcinoma

Expression and Clincal Significance of COX2 and VEGF in Human Non-Small Cell Lung Carcinoma